Our faculty secure major research grants from various National Institutes of Health as well as private sources.
Chelsie Armbruster, PhD
Conserved Proteus mirabilis genetic requirements for colonization of the catheterized urinary tract. Chelsie Armbruster (Co-Investigator). National Institute of Diabetes and Digestive and Kidney Diseases. $1,684,580. 9/1/2019-5/1/2024.
TARGETING M. CATARRHALIS FOR PREVENTION AND TREATMENT OF OTITIS MEDIA. Anthony Campagnari (Principal Investigator). National Institutes of Deafness and Communicative Disorders. $1,982,425. 5/1/2016-4/1/2021.
Pneumococcal transition from nasopharyngeal biofilm carriage to otitis media. Anthony Campagnari (Principal Investigator). NIH/NIDCD. $1,840,000. 3/1/2014-2/1/2019.
Evaluation of a Specific Cytotoxic Agent and Identification of a New Targetable Receptor for Human TripleNegative Breast Cancer. Terry Connell (Co-Investigator). Dept. of Defense, BCRP, Breakthrough Award Levels 1. $375,000. 4/1/2018-3/1/2020.
Specific induction of lethal autophagy in triple-negative breast cancer cells. Terry Connell (Principal Investigator). National Cancer Institute, NIH. $275,000. 4/1/2017-3/1/2019.
Regulation of Intrinsic Caspofungin Resistance in C. neoformans. John Panepinto (Principal Investigator). National Insitute of Allergy and Infectious Diseases. $412,353. 8/1/2018-7/1/2020.
Stress Responsive Reprogramming of Translating mRNA Pools in C. neoformans. John Panepinto (Principal Investigator). NIAID. $1,932,170. 5/1/2017-4/1/2022.
Control of Host-Induced C. neoformans Morphogenesis by Protein Arginine Methylation. John Panepinto (Principal Investigator). American Heart Association Founders Affiliate. $154,000. 1/1/2017-12/1/2019.
Stress responsive reprogramming of translating mRNA pools in C. neoformans. Yijun Sun (Co-Investigator). NIH. $2,000,000. 5/1/2017-4/1/2022.
Methylglyoxal could mediate the relationship between infections and diabetes: a method development and feasibility study. Yijun Sun (Co-Investigator). UB-the Innovative Micro-Programs Accelerating Collaboration in Themes Program. $31,000. 7/1/2016-6/1/2017.
Developing advanced algorithms to address major computational challenges in current microbiome research. Yijun Sun (Principal Investigator). NIH. $973,277. 7/1/2016-6/1/2019.
PPI related gut microbiota dysbiosis role in diabetic nephropathy: A cross-sectional analysis. Yijun Sun (Co-Investigator). UB - GEM Pilot Study Program. $34,000. 7/1/2016-6/1/2017.
Pilot study of the placental, oral and gut microbiome related to pregnancy outcomes. Yijun Sun (Co-Investigator). UB - GEM Pilot Study Program. $34,000. 7/1/2016-6/1/2017.
The airway microbiome and lung cancer in a COPD cohort. Yijun Sun (Co-Investigator). UB - GEM Pilot Study Program. $34,000. 7/1/2016-6/1/2017.
Oral microbiome and periodontitis: a prospective study in postmenopausal women. Yijun Sun (Co-Investigator), Michael Buck (Co-Investigator). NIH. $4,000,000. 7/1/2014-7/1/2019.
Derivation of molecular signatures for accurate prostate cancer prognosis using both annotated and non-annotated tissue samples. Yijun Sun (Principal Investigator). SUNY Research Foundation. $96,495. 1/1/2014-12/1/2016.
Deciphering the mechanism of how GATA3 controls the fate of regulatory T cells at mucosal sites. Elizabeth Wohlfert (Principal Investigator). Crohn‘s and Colitis Foundation of America. $268,500. 11/1/2013-11/1/2016.